An enzyme inhibitor that helps repair DNA damage may provide a new way to boost the effectiveness of radiation therapy for a lethal type of brain cancer.
Bristol-Myers Squibb will collaborate with Adaptive Biotechnologies to develop immunological biomarkers for cancer, representing another step forward in the development of personalized medicine.
In an ambitious effort to find more personalized treatments for cancer and other complex diseases, Oregon Health & Science University in Portland and Intel are teaming up to develop new computing technologies to map an individual's genetic profile more quickly, precisely and cost-effectively.
Scientists have identified multiple metabolic expression changes associated with cancer as well as hundreds of new potential drug targets that could cut off a tumor's fuel supply or interfere with its ability to produce essential building blocks.
Scientists think they've found a link between antibody makeup and ethnicity--evidence that that some ethnic groups may be more susceptible to certain diseases or respond to diseases differently than people of other backgrounds.
The agreement follows the start of a Phase I study of the compound, EPZ-5676, for which biotech giant Celgene has partnered with the startup for development outside the U.S.
Agios Pharmaceuticals may be one step closer to finding a breakthrough approach to treat cancer in a more personalized fashion.
Researchers at Merck are developing a class of new drugs that could help improve treatment options for patients with certain cancers driven by genetic mutations.
In a small study mounted at the University of Pennsylvania, a novel combination approach using a personalized therapeutic vaccine made from dendritic cells primed with a patient's tumor cells was successfully used to fight advanced ovarian cancer.
Agios has teamed up with Foundation Medicine to find patients with the genetic profiles most suited to treatment on Agios therapies concerning two cancer metabolism targets.